Indium (111In) biciromab

{{DISPLAYTITLE:Indium (¹¹¹In) biciromab}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458273546

| drug_name = Indium (¹¹¹In) biciromab

| type = mab

| mab_type = Fab'

| source = o

| target = Fibrin II, beta chain

| tradename = FibriScint

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category = N/A

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Withdrawn

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 138783-13-8

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D03111

| chemical_formula =

| molecular_weight =

}}

Indium (¹¹¹In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.{{cite journal | vauthors = King DJ, Adair JR | title = Recombinant antibodies for the diagnosis and therapy of human diseases | journal = Current Opinion in Drug Discovery & Development | volume = 2 | issue = 2 | pages = 110–7 | date = March 1999 | pmid = 19649936 }} It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,{{cite web | url = http://www.answers.com/topic/centocor-inc | work = Answers.com | title = Centocor Ortho Biotech Products, L.P. }} but was withdrawn during clinical trials.{{cite web | url = https://www.diagnosticimaging.com/view/centocor-withdraws-imaging-agent-applications | work = DiagnosticImaging.com | title = Centocor withdraws imaging agent applications }}